Drug evaluation: Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids

Current Opinion in Investigational Drugs

Volumn 8, Issue 10, 2007, Pages 859-866

  Orihuela, P A ^a  

^a UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 19 NORPREGNA 4,9 DIENE 3,20 DIONE; ANTIGESTAGEN; CONTRACEPTIVE AGENT; HRP 2000; LEVONORGESTREL; MIFEPRISTONE; PLACEBO; RTI 3021 012; RTI 3021 022; ULIPRISTAL; UNCLASSIFIED DRUG; VA 2914; PREGNANE DERIVATIVE; PROGESTERONE RECEPTOR; ULIPRISNIL ACETATE;

CLINICAL TRIAL; CONTRACEPTION; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; GUINEA PIG; HUMAN; MONKEY; NONHUMAN; OVULATION; RANDOMIZATION; RAT STRAIN; REVIEW; RHESUS MONKEY; SINGLE DRUG DOSE; UTERUS MYOMA; ANIMAL; DRUG ANTAGONISM; FEMALE; LEIOMYOMA; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; CONTRACEPTIVE AGENTS, FEMALE; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LEIOMYOMA; NORPREGNADIENES; RECEPTORS, PROGESTERONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34848917528     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. 87152 Antiprogestins, a new form of endocrine therapy for human breast cancer. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J CANCER RES 1989 49 11 2851-2856
2. 112249 Mifepristone (RU 486) treatment of meningiomas. Lamberts SW, Tanghe HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW, de Jong H J NEUROL NEUROSURG PSYCHIAT 1992 55 6 486-490
3. 174741 Annual report - Schering AG - 1994. Schering AG ANNUAL REPORT 1994 March 30
4. 258530 Antiprogestins and iatrogenic glucocorticoid resistance. Koper JW, Molijn GJ, van Uffelen CJC, Stigter E, Lamberts SW LIFE SCI 1997 60 9 617-624
5. 301066 Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple or continuous doses to rats. Reel JR, Hild-Petito S, Blye RP CONTRACEPTION 1998 58 2 129-136
6. 323542 The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins. Wagner BL, Pollio G, Giangrande P, Webster JC, Breslin M, Mais DE, Cook CE, Vedeckis WV, Cidlowski JA, McDonnell DP ENDOCRINOLOGY 1999 140 3 1449-1458
7. 488642 Antiprogestins: Mechanism of action and contraceptive potential. Spitz IM, Croxatto HB, Robbins A ANNU REV PHARMACOL TOXICOL 1996 36 47-81
8. 491257 Abbott Laboratories reviews pharmaceutical research and development transformation at meeting for investors and financial analysts. Abbott Laboratories PRESS RELEASE 2003 May 29
9. 502784 Laboratoire HRA Pharma - A public health company. HRA Pharma COMPANY WORLD WIDE WEB SITE 2003 August 26
10. 511935 Nycomed 2002. Nycomed Holding A/S ANNUAL REPORT 2002 December 31
11. 512005 Company profile as of December 31, 2002 - HRA Pharma. HRA Pharma COMPANY BROCHURE 2002 December 31
12. 649678 Drug development pipeline: VA-2914. Nycomed COMPANY COMMUNICATION 2006 February 10
13. 674137 Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and upregulates caspase-3 and poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson EDB, Maruo T J CLIN ENDOCRINOL METAB 2005 90 2 953-961
14. 674138 In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. Attardi BJ, Burgenson J, Hild SA, Reel JR J STEROID BIOCHEM MOL BIOL 2004 88 3 277-288
15. 674139 Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M STEROIDS 2003 68 10-13 1013-1017
16. 674140 Pharmacologic properties of CDB(VA)-2914. Gainer EE, Ulmann A STEROIDS 2003 68 10-13 1005-1011
17. 674141 Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Passaro MD, Piquion J, Mullen N, Sutherland D, Zhai S, Figg WD, Blye R, Nieman LK HUM REPROD 2003 18 9 1820-1827
18. 674146 Effect of a 17α-(3-hydroxypropyl)-17β- acetyl substituent pattern on the glucocorticoid and progestin receptor binding of 11β-arylestra-4,9-dien-3-ones. Cook CE, Raje P, Lee DY, Kepler JA ORG LETT 2001 3 7 1013-1016
19. 674147 A practical large-scale synthesis of 17α-acetoxy- 11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4, 9-diene-3,20-dione (CDB-2914). Rao PN, Acosta CK, Bahr ML, Burdett JE, Cessac JW, Morrison PA, Kim HK STEROIDS 2000 65 7 395-400
20. 674148 Circulating concentrations of the antiprogestins CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration. Larner JM, Reel JR, Blye RP HUM REPROD 2000 15 5 1100-1106
21. 674149 A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Stratton P, Hartog B, Hajizadeh N, Piquion J, Sutherland D, Merino M, Lee YJ, Nieman LK HUM REPROD 2000 15 5 1092-1099
22. 674150 CDB-2914: Anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hild SA, Reel JR, Hoffman LH, Blye RP HUM REPROD 2000 15 4 822-829 • A preclinical study clearly demonstrating the antifertility and postcoital contraceptive effectiveness of ulipristal in rats and rabbits.
23. 674151 Effects of progesterone receptor blockers on human granulosaluteal cell culture secretion of progesterone, estradiol, and relaxin. VandeVoort CA, Overstreet JW, Lasley BL, Stewart DR BIOL REPROD 2000 62 1 200-205
24. 674161 Effects of two antiprogestins on early pregnancy in the longtailed macaque (Macaca fascicularis). Tarantal AF, Hendrickx AG, Matlin SA, Lasley BL, Gu QQ, Thomas CA, Vince PM, Van Look PF CONTRACEPTION 1996 54 2 107-115
25. 674164 The anti-progestin CDB 2914 has no antifertility effect in male rats. Wang C, Sinha-Hikim A, Leung A CONTRACEPTION 1995 51 3 215-218
26. 674166 A comparison of the pregnancy-terminating potencies of three anti-progestins in guinea-pigs, and the effects of sulprostone. Poyser NL, Forcelledo ML PROSTAG LEUKOT ESSENT FATTY ACIDS 1994 50 5 245-247
27. 674401 Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, Johansson ED, Maruo T HUM REPROD 2006 21 9 2408-2416
28. 749360 HRA begins US phase III trial of emergency contraceptive. HRA Pharma PRESS RELEASE 2006 December 07
29. 778062 HRA starts pivotal emergency contraception phase III trial of Ella. HRA Pharma PRESS RELEASE 2007 March 26
30. 778205 Progesterone receptor modulator for emergency contraception - A randomized controlled trial. Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J OBSTET GYNECOL 2006 108 5 1089-1097 • A phase II trial comparing the emergency contraceptive efficacy of ulipristal with that of levonorgestrel. Ulipristal was at least as effective as levonorgestrel.
31. 787580 Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Wu Y, Guo SW GYNECOL OBSTET INVEST 2006 62 4 193-205
32. 809540 International nonproprietary names for pharmaceutical substances (INN). INTERNET SITE 2007 List 58 http://www.mednet. who.int
33. 819829 Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Maruo T, Ohara N, Matsuo H, Xu Q, Chen W, Sitruk-Ware R, Johansson ED CONTRACEPTION 2007 75 6 Suppl 99-103
34. 822355 The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Williams ARW, Critchley HOD, Osei J, Ingamells S, Cameron IT, Han C, Chwalisz K HUM REPROD 2007 22 6 1696-1704
35. 822389 HRA Pharma: Product pipeline. HRA Pharma COMPANY WORLD WIDE WEB SITE 2006 September 21
36. 822593 NCT00290251: Treatment of uterine fibroids with the selective progesterone receptor modulator CDB-2914. National Institutes of Health Clinical Center CLINICALTRIALS.GOV 2007 August 02
37. 822892 Product research and development: Female contraceptives. Population Council COMPANY WORLD WIDE WEB SITE 2007 August 13
38. 822906 Selective progesterone receptor modulators and progesterone antagonists: Mechanisms of action and clinical applications. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM HUM REPROD UPDATE 2005 11 3 293-307
39. 823531 The selective progesterone receptor modulator CDB-2914 has estrogenic and anti-estrogenic effects in menopausal women. Christian R, Stratton P, Merino MJ, Segar J, Wesley R, Barnhart L, Nieman LK ANN MEET ENDOCRINE SOC 2002 84 Abs 3-38
40. 826267 Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W ENDOCR REV 2005 26 3 423-438
41. 826268 Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Fiala C, Gemzel-Danielsson K CONTRACEPTION 2006 74 1 66-86
42. 826269 A novel estrogen-free oral contraceptive pill for women: Multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Lakha F, Ho PC, Van der Spuy ZM, Dada K, Elton R, Glasier AF, Critchley HO, Williams AR, Baird DT HUM REPROD 2007 22 9 2428-2436
43. 826270 Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: Comparison between RU486 and a new 21-substituted-19-nor-progestin. Wiehle RD, Christov K, Mehta R ONCOL REP 2007 18 1 167-174
44. 827064 NCT00411684: Safety and efficacy of CDB-2914 for emergency contraception. HRA Pharma CLINICALTRIALS.GOV 2006 December 13
45. 827065 NCT00089414: The treatment of menstrually-related mood disorders with extended versus interrupted oral contraceptives. National Institutes of Health CLINICALTRIALS.GOV 2007 June 27
46. 827278 Mifepristone (RU 486) for Alzheimer's disease. Pomara N, Doraiswamy PM, Tun H, Ferris S NEUROLOGY 2002 58 9 1436
47. 827286 Alterations in the pituitary-thyroid and pituitary-adrenal - axesconsequences of long-term mifepristone treatment. Heikinheimo O, Ranta S, Grunberg S, Lähteenmäki P, Spitz IM METABOLISM 1997 46 3 292-296
48. 827291 Alterations in sex steroids and gonadotropins in postmenopausal women subsequent to long-term mifepristone administration. Heikinheimo O, Ranta S, Grunberg S, Spitz IM STEROIDS 2000 65 10-11 831-836
49. 827293 Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Newfield RS, Spitz IM, Isacson C, New MI CLIN ENDOCRINOL 2001 54 3 399-404
50. 827318 Drug development pipeline: Ulipristal/CDB-2914/Ella. HRA Pharma COMPANY COMMUNICATION 2007 August 30